Trade Harmony Biosciences Holdings, Inc. - HRMY CFD

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc. is a holding company. The Company through its subsidiary, Harmony Biosciences, LLC., operates as a pharmaceutical company, which is focused on therapies for patients suffering from central nervous system disorders. It provides treatment options for people living with rare and orphan diseases, with an emphasis on central nervous system disorders, patients living with narcolepsy. It enables to know narcolepsy and provides information and resources to individuals who live with, and healthcare professionals who treat patients with, this disorder. The Company’s product, WAKIX (pitolisant), is a molecule with mechanism of action (MOA), designed to histamine signaling in the brain by binding to H3 receptors. It also provides HBS-102, a Melanin Concentrating Hormone Receptor One (MCHR1) antagonist that offers treatment of narcolepsy, including the symptoms of Rapid Eye Movement (REM) sleep dysregulation, such as cataplexy, hallucinations and sleep paralysis.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Harmony Biosciences Holdings Inc revenues increased 91% to $305.4M. Net income applicable to common stockholders totaled $34.6M vs. loss of $63.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Interest expense, net decrease of 15% to $24M (expense), Other income (expense).